An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy
Vagal Nerve Simulation (VNS) Therapy
+ Best Medical Practive
Maladies du cerveau+2
+ Maladies du système nerveux central
+ Épilepsie
Étude thérapeutique
Résumé
Date de début de l'étude : 1 février 2006
Date à laquelle le premier participant a commencé l'étude.This is a post-market medical device study. This study will compare best medical practice with or without adjunctive VNS Therapy in patients who are 16 years and older with pharmaco-resistant partial epilepsy. The Sponsor, Cyberonics, provides funding for this study. Patients are followed for 26 months, 24 of those months are following the initiation of treatment. No study sites will be permitted to enroll study subjects until Institutional Review Board (IRB)/Ethics Committee (EC) approval has been received.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.122 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 16 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: * Patient has confirmed partial onset seizures. * Seizure activity is not adequately controlled by patient's current AED regimen. * Patient is between 16 and 75 years of age. * Patient is able to give accurate seizure counts and health outcomes information. Patient is able to complete study instruments with minimal assistance. * Patient has previously failed at least 3 AEDs in single or combination use. * During baseline evaluation period, patient should take at least 1 AED. * Patient should have confirmed epilepsy for a minimum of 2 years. * Patient's AED regimen is stable for at least 1 month prior to enrolment. * Patient has at least 1 objective partial onset seizure per month during the 2 months prior to enrolment. * Patient or legal guardian understands study procedures and has voluntarily signed an informed consent in accordance with institutional and local regulatory policies. Exclusion Criteria: * Patient has pseudoseizures or a history of pseudoseizures. * Patient has idiopathic generalised epilepsy or unclassified epilepsy. * Patient has ever received direct brain stimulation (cerebella or thalamic) for treatment of epilepsy. * Patient has had a unilateral or bilateral cervical vagotomy. * Patient has a history of non-compliance with the completion of a seizure diary. * Patient has taken an investigational drug within a period of 3 months prior to inclusion. * Patient is currently using another investigational medical device. * Patient has a significant cardiac or pulmonary condition currently under treatment. * Patient has previously undergone brain surgery. * Patient has a demand cardiac pacemaker, implantable defibrillator, or other implantable stimulator. * Patient currently lives more than 2 hours from the study site or plans to relocate to a location more than 2 hours from the study site within one year of enrolment in the Study.
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.2 groupes d'intervention sont désignés dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
ExpérimentalGroupe II
Comparateur actifObjectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 48 sites
ULB-Hôpital Erasme, Centre de référence pour le traitement de l'épilepsie réfractaire - Neurologie
Brussels, BelgiumOuvrir ULB-Hôpital Erasme, Centre de référence pour le traitement de l'épilepsie réfractaire - Neurologie dans Google MapsUZ Gent, Department of Neurology, 1K12/A
Ghent, BelgiumFoothills Hospital, Neurology Department
Calgary, CanadaQEII Health Sciences Centre
Halifax, Canada